Immunome annual stock-based compensation
2019
2020
2021
2022
2023
2024
2025
Immunome Stock-Based Compensation Growth & History (IMNM)
Immunome's stock-based compensation was $25.7M for fiscal 2025.
View full Immunome company overviewImmunome annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $25.7M | $9.9M | +63.13% |
| 2024 | 2024-12-31 | $15.7M | $9.5M | +153.06% |
| 2023 | 2023-12-31 | $6.2M | $891,000 | +16.71% |
| 2022 | 2022-12-31 | $5.3M | $1.9M | +54.64% |
| 2021 | 2021-12-31 | $3.4M | $2.8M | +455.23% |
| 2020 | 2020-12-31 | $621,000 | $607,000 | +4335.71% |
| 2019 | 2019-12-31 | $14,000 | — | — |
Immunome quarterly stock-based compensation
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $8.8M | $3.5M | +64.56% |
| Q1 2026 | 2026-03-31 | $8.0M | $2.3M | +39.45% |
| Q4 2025 | 2025-12-31 | $7.9M | $2.4M | +44.30% |
| Q3 2025 | 2025-09-30 | $6.7M | $1.9M | +37.92% |
| Q2 2025 | 2025-06-30 | $5.3M | $2.1M | +65.70% |
| Q1 2025 | 2025-03-31 | $5.7M | $3.5M | +164.15% |
| Q4 2024 | 2024-12-31 | $5.5M | $2.6M | +89.73% |
| Q3 2024 | 2024-09-30 | $4.9M | $3.8M | +351.71% |
| Q2 2024 | 2024-06-30 | $3.2M | $2.2M | +212.39% |
| Q1 2024 | 2024-03-31 | $2.2M | $935,000 | +76.39% |
| Q4 2023 | 2023-12-31 | $2.9M | $1.5M | +112.77% |
| Q3 2023 | 2023-09-30 | $1.1M | −$257,000 | −19.18% |
| Q2 2023 | 2023-06-30 | $1.0M | −$294,000 | −22.16% |
| Q1 2023 | 2023-03-31 | $1.2M | −$86,000 | −6.56% |
| Q4 2022 | 2022-12-31 | $1.4M | $136,000 | +11.16% |
| Q3 2022 | 2022-09-30 | $1.3M | $185,000 | +16.02% |
| Q2 2022 | 2022-06-30 | $1.3M | $578,000 | +77.17% |
| Q1 2022 | 2022-03-31 | $1.3M | $985,000 | +303.08% |
| Q4 2021 | 2021-12-31 | $1.2M | $900,000 | +282.13% |
| Q3 2021 | 2021-09-30 | $1.2M | $1.0M | +887.18% |
| Q2 2021 | 2021-06-30 | $749,000 | $710,000 | +1820.51% |
| Q1 2021 | 2021-03-31 | $325,000 | $179,000 | +122.60% |
| Q4 2020 | 2020-12-31 | $319,000 | — | — |
| Q3 2020 | 2020-09-30 | $117,000 | $116,000 | +11600.00% |
| Q2 2020 | 2020-06-30 | $39,000 | — | — |
| Q1 2020 | 2020-03-31 | $146,000 | — | — |
| Q3 2019 | 2019-09-30 | $1,000 | — | — |
Immunome stock-based compensation trends
Over the last five fiscal years, Immunome's stock-based compensation increased from $621,000 to $25.7M, a change of $25.1M. The latest reported quarter, Q2 2026, shows $8.8M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Immunome source filings ↗